European Autism Interventions - A Multicentre Study for Developing New Medications (EU-AIMS) - is the largest single grant for autism in the world, and the largest for the study of any mental health disorder in Europe. 

EU-AIMS involves a novel collaboration between organisations representing affected individuals and their famillies (Autism Speaks), academia and Industry who for the first time in the world have come together to develop the infrastructure underpinning new treatments for autism. Patient organizations, academic and industry join forces to develop and assess novel treatment approaches for autism.

An international consortium of scientists, led by Roche and King's College London, has launched one of the largest ever research academic-industry collaboration projects to find new methods for the development of drugs for autism spectrum disorder (ASD).  

Collaboration with other projects and groups

In the field of public health, EU-AIMS collaborates with other groups and projectsto improve quality of life and prognosis for people with autism:

  • The European Babysibs Autism Research Network (Eurosibs)
  • Autism Spectrum Disorders in Europe (ASDEU)

Major goals of the project EU-AIMS 

We will couple this integrated research effort with the development of new training opportunities and the implementation of new analytical approaches.

EU-AIMS major goals

Watch the EU-AIMS video below to get a better idea about the programme and what we are doing for autism research.